The anti-PSMA antibody-drug conjugate (ADC) ARX517 has been granted fast track designation by the US Food and Drug Administration for the treatment of metastatic castration resistant prostate cancer (mCRPC).
Antibody-drug conjugates (ADC) and Bispecific antibody constructs represent the most recent type of precision cancer medicines being developed for the treatment of cancer including patients with non–small cell lung cancer (NSCLC), and small cell lung cancer (SCLC).
Antibody-drug-conjugates work by delivering cytotoxic chemotherapy (“payload”) to cancer cells via a linker attached to a monoclonal antibody that binds to a specific target expressed on the cancer cells.
About mCRPC
Prostate cancer is initially a hormonally sensitive disease that can often be controlled for long periods with androgen-deprivation therapy (ADT). When prostate cancer stops responding to this treatment, it is referred to as hormone-refractory prostate cancer or metastatic castration resistant prostate cancer (mCRPC). mCRPC is a challenging phase of the disease to treat because the cancer has spread to distant sites in the body and does not respond to treatment with standard hormonal therapy – new treatments are sorely needed.
About ARX517
ARX517 is and ADC composed of a fully humanized anti-PSMA monoclonal antibody linked to AS269, a type of chemotherapy that inhibits microtubule formation necessary for cell division. PSMA is expressed on the surface of over 90% of mCRPC cells and not present on normal cells. This makes PSMA an ideal target for delivery of ARX517 which is internalized upon antibody binding to PSMA and delivers its payload to the cell interior.
Connect With Others for Support and information
CancerConnect was the first social network created for people with prostate cancer. Founded by oncologists to support prostate cancer patients and their caregivers, over 40 million individuals have accessed CancerConnect programs since 1997. CancerConnect is used by leading cancer centers like Dana Farber, Roswell Park and The James at Ohio State to support their patients. Join the conversation, ask questions, share your experience, and learn how the best cancer centers are treating prostate cancer from others. Share your experience, ask a question, or start a conversation by posting on CancerConnect.
References
- ARX517, Ambrx’s proprietary anti-PSMA ADC, shows encouraging single-agent safety and efficacy data in patients with advanced prostate cancer. News release. Ambrx Biopharma, Inc. February 16, 2023. Accessed July 19, 2023. https://ir.ambrx.com/news/news-details/2023/ARX517-Ambrxs-Proprietary-Anti-PSMA-ADC-Shows-Encouraging-Single-Agent-Safety-and-Efficacy-Data-in-Patients-with-Advanced-Prostate-Cancer/default.aspx
- https://www.onclive.com/view/fda-awards-fast-track-designation-to-arx517-for-metastatic-castration-resistant-prostate-cancer
